Seraticin

About

Researchers have developed a potentially valuable treatment for fighting infections, including the MRSA. This technology, trademark under the name SERATICIN® which has been in development for over ten years, is based on maggot secretions which have been used in ancient times to clean wounds. Work has established the definitive chemical structure and a method for its synthesis. SERATICIN® offers the prospect of a highly effectively antibacterial candidate in a format compatible with modern drug delivery modes. Given the lack of side effects from the original treatment using live maggots, the prospect that trials are successful is particularly high. The invention is offered for exclusive or non-exclusive licence. A patent has been granted.